|
業務類別
|
Biotechnology |
|
業務概覽
|
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
| 公司地址
| 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421 |
| 電話號碼
| +1 617 503-6500 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.curis.com |
| 員工數量
| 24 |
| Dr. Ahmed M. Hamdy, M.D. |
Chief Medical Officer |
-- |
24/03/2026 |
| Mr. James E. Dentzer |
Director, President and Chief Executive Officer |
美元 672.20K |
21/04/2026 |
| Dr. Jonathan B. Zung, PhD |
Chief Development Officer |
美元 519.90K |
24/03/2026 |
| Ms. Diantha Duvall |
Chief Financial Officer and Principal Accounting Officer |
美元 514.20K |
24/03/2026 |
|
|
| Mr. Martyn D. Greenacre |
Chairman of the Board |
21/04/2026 |
| Mr. James E. Dentzer |
Director, President and Chief Executive Officer |
21/04/2026 |
| Dr. Kenneth I. Kaitin,PhD |
Independent Director |
21/04/2026 |
| Dr. Marc Rubin,M.D. |
Independent Director |
21/04/2026 |
| Dr. Anne E. Borgman, M.D. |
Independent Director |
21/04/2026 |
| Dr. John A. Hohneker, M.D. |
Independent Director |
21/04/2026 |
|
|
|
|
